Alloimmune Thrombocytopenia

Platelets

Volumn , Issue , 2013, Pages 953-970

  Kaplan, Cécile ^a   Ni, Heyu ^b   Freedman, John ^b  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882604043     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00046-8     Document Type: Chapter

References (174)

1. Harrington W.J., Sprague C.C., Minnich V., Moore C.V., Aulvin R.C., Dubach R. Immunologic mechanisms in neonatal and thrombocytopenic purpura. Ann Intern Med 1953, 38:433-469.
2. Shulman N.R., Aster R.H., Leitner A., Hiller M.C. A new syndrome of post-transfusion immunologic purpura. J Clin Invest 1960, 39:1028-1029.
3. Levine P., Burnham L., Katzin E.M., Vogel P. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis. Am J Obstet Gynecol 1941, 42:925-927.
4. Mueller-Eckhardt C., Kiefel V., Grubert A., Kroll H., Weisheit M., Schmidt S., et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989, 1:363-366.
5. Bertrand G., Drame M., Martageix C., Kaplan C. Prediction of the fetal status in non-invasive management of alloimmune thrombocytopenia. Blood 2011, 117:3209-3213.
6. Kaplan C., Forestier F., Daffos F., Tchernia G., Waters A. Management of fetal and neonatal alloimmune thrombocytopenia. Transfus Med Rev 1996, 10:233-240.
7. Hohlfeld P., Forestier F., Kaplan C., Tissot J.D., Daffos F. Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994, 84:1851-1856.
8. Dreyfus M., Kaplan C., Verdy E., Schlegel N., Durand-Zaleski I., Tchernia G., et al. Frequency of immune thrombocytopenia in newborns: a prospective study. Blood 1997, 89:4402-4406.
9. Spencer J.A., Burrows R.F. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis. Aust N Z J Obstet Gynaecol 2001, 41:45-55.
10. Kaplan C., Daffos F., Forestier F., Morel M.C., Chesnel N., Tchernia G. Current trends in neonatal alloimmune thrombocytopenia diagnosis and therapy. Platelet Immunology: Fundamental and Clinical Aspects 1991, 267-278. John Libbey-Eurotex, Paris. C. Kaplan-Gouet, N. Schlegel, J. Ch Salmon, J. Mac Gregor (Eds.).
11. Pahal G.S., Jauniaux E., Kinnon C., Thrasher A.J., Rodeck C.H. Normal development of human fetal hematopoiesis between eight and seventeen weeks' gestation. Am J Obstet Gynecol 2000, 183:1029-1034.
12. Forestier F., Daffos F., Galacteros F., Bardakjian J., Rainaut M., Beuzard Y. Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986, 20:342-346.
13. Wiedmeier S.E., Henry E., Sola-Visner M.C., Christensen R.D. Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system. J Perinatol 2009, 29:130-136.
14. Castle V., Andrew M., Kelton J.G., Giron D., Johnston M., Carter C. Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986, 108:749-755.
15. Durand-Zaleski I., Schlegel N., Blum-Boisgard C., Uzan S., Dreyfus M., Kaplan C., et al. Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs. Am J Perinatol 1996, 13:423-431.
16. Williamson L.M., Hackett G., Rennie J., Palmer C.R., Maciver C., Hadfield R., et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PLA1, Zwa) as determined by antenatal screening. Blood 1998, 92:2280-2287.
17. Turner M.L., Bessos H., Fagge T., Harkness M., Rentoul F., Seymour J., et al. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a. Transfusion 2005, 45:1945-1956.
18. Kjeldsen-Kragh J., Killie M.K., Tomter G., Golebiowska E., Randen I., Hauge R., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007, 110:833-839.
19. Davoren A., McParland P., Barnes C.A., Murphy W.G. Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002, 55:289-292.
20. Bussel JB. Neonatal alloimmune thrombocytopenia (NAIT): a prospective case accumulation study. Pediatr Res 1988, 23:337. [abstract].
21. Semple J.W., Freedman J. Recipient antigen-processing pathways of allogeneic platelet antigens: essential mediators of immunity. Transfusion 2002, 42:958-961.
22. Semple J.W., Bang K.W.A., Speck E.R., Blanchette V.S., Freedman J. Recipient mechanisms of alloimmunity: antigen processing mediates IgG immunity against donor platelets. Molecular Biology in Blood Transfusion 2000, 135-145. Kluwer Academic Publishers, Dordrecht, Netherlands. C. Smit Sibinga, H.G. Klein (Eds.).
23. von dem Borne A.E., Kaplan C., Minchinton R. Nomenclature of human platelet alloantigens. Blood 1995, 85:1409-1410.
24. Metcalfe P., Watkins N.A., Ouwehand W.H., Kaplan C., Newman P., Kekomäki R., et al. Nomenclature of human platelet antigens. Vox Sang 2003, 85:240-245.
25. Simsek S., Faber N.M., Bleeker P.M., Vlekke A.B.J., Huiskes E., Goldschmeding R., et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood 1993, 81:835-840.
26. Liu T.C., Shih M.C., Lin C.L., Lin S.F., Chen C.M., Chang J.G. Gene frequencies of the HPA-1 to HPA-8w platelet antigen alleles in Taiwanese, Indonesian, and Thai. Ann Hematol 2002, 81:244-248.
27. Halle L., Bach K.H., Martageix C., Bianchi F., Lê T., Kim T., et al. Eleven human platelet systems studied in the Vietnamese and Ma'ohis Polynesian populations. Tissue Antigens 2004, 63:34-40.
28. Halle L., Bigot A., Mulen-Imandy G., M'Bayo K., Jaeger G., Anani L., et al. HPA polymorphism in sub-Saharan African populations: Beninese, Cameroonians, Congolese, and Pygmies. Tissue Antigens 2005, 65:295-298.
29. Brouk H., Halle L., Bertrand G., Neche F.Z., Ouelaa H., Kaplan C. Human platelet antigen allele frequencies in different Algerian populations. Tissue Antigens 2010, 75:673-678.
30. a) neonatal alloimmune thrombocytopenia: clinical and immunological analysis of 39 cases. Br J Haematol 1991, 78:425-429.
31. Glade-Bender J., McFarland J.G., Kaplan C., Porcelijn L., Bussel J.B. Anti-HPA-3a induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001, 138:862-867.
32. Ohto H., Miura S., Ariga H., Ishii T., Fujimori K., Morita S., et al. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Medicine 2004, 14:399-408.
33. aa): genetic determination of a new platelet-specific alloantigen on glycoprotein IIIa and its expression in COS-7 cells. Blood 1997, 89:2422-2428.
34. Kroll H., Kiefel V., Santoso S., Sra Mueller-Eckhardt C. a private platelet antigen on glycoprotein IIIa associated with neonatal alloimmune thrombocytopenia. Blood 1990, 76:2296-2302.
35. Berry J.E., Murphy C.M., Smith G.A., Ranasinghe E., Finberg R., Walton J., et al. Detection of Gov system antibodies by MAIPA reveals an immunogenicity similar to the HPA-5 alloantigens. Br J Haematol 2000, 110:735-742.
36. Jallu V., Meunier M., Brement M., Kaplan C. A new platelet polymorphism Duv(a+), localized within the RGD binding domain of glycoprotein IIIa, is associated with neonatal thrombocytopenia. Blood 2002, 99:4449-4456.
37. Santoso S., Kiefel V., Richter I.G., Sachs U.J., Rahman A., Carl B., et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the beta(3) integrin: the Oe(a) alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002, 99:1205-1214.
38. Bertrand G., Jallu V., Saillant D., Kervran D., Martageix C., Kaplan C. The new platelet alloantigen Cab a: a single point mutation Gln 716 His on the alpha 2 integrin. Transfusion 2009, 49:2076-2083.
39. Jallu V., Dusseaux M., Kaplan C. A new Ser472Asn (Cab2(a+)) polymorphism localized within the aIIb "thigh" domain is involved in neonatal thrombocytopenia. Transfusion 2011, 51:393-400.
40. Davoren A., Curtis B.R., Aster R.H., McFarland J.G. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. Transfusion 2004, 44:1220-1225.
41. Kroll H., Yates J., Santoso S. Immunization against a low-frequency human platelet alloantigen in fetal alloimmune thrombocytopenia is not a single event: characterization by the combined use of reference DNA and novel allele-specific cell lines expressing recombinant antigens. Transfusion 2005, 45:353-358.
42. a) feto-maternal alloimmunization, a clinically severe neonatal thrombocytopenia: difficulties in diagnosis and therapy, report on 8 families. Transfusion 2005, 45:1799-1803.
43. a) is an important cause of neonatal alloimmune thrombocytopenia. Transfusion 2005, 45:1487-1495.
44. Bertrand G., Bianchi F., Alexandre M., Quesne J., Chenet C., Martageix C., et al. HPA-13bw neonatal alloimmune thrombocytopenia and low frequency alloantigens: case report and review of the literature. Transfusion 2007, 47:1510-1513.
45. Ertel K., Al-Tawil M., Santoso S., Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005, 45:366-373.
46. Curtis B.R., Ali S., Glazier A.M., Ebert D.D., Aitman T.J., Aster R.H. Isoimmunization against CD36 (glycoprotein IV): description of four cases of neonatal isoimmune thrombocytopenia and brief review of the literature. Transfusion 2002, 42:1173-1179.
47. Léticée N., Kaplan C., Lémery D. Pregnancy in mother with Glanzmann's thrombasthenia and isoantibody against GPIIb-IIIa: is there a foetal risk?. Eur J Obst Gynecol Reprod Biol 2005, 121:139-142.
48. Li C., Piran S., Chen P., Lang S., Zarpellon A., Jin J.W., et al. Maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011, 121:4537-4547.
49. Kumpel B.M., Sibley K., Jackson D.J., White G., Soothill P.W. Ultrastructural localization of glycoprotein IIIa (GP IIIa, beta 3 integrin) on placental syncytiotrophoblast microvilli: implications for platelet alloimmunization during pregnancy. Transfusion 2008, 48:2077-2086.
50. Semple J.W., Freedman J. The basic immunology of platelet-induced alloimmunisation. Current Issues in Platelet Transfusion Therapy and Platelet Alloimmunity 1999, 77-101. AABB Press, Bethesda, MD. T.S. Kickler, J.H. Herman (Eds.).
51. Valentin N., Vergracht A., Bignon J.D., Cheneau M.L., Blanchard D., Kaplan C., et al. HLA-DRw52a is involved in alloimmunization against PL-A1 antigen. Hum Immunol 1990, 27:73-79.
52. A1) is strongly associated with both HLA-DR3*0101 and HLA-DQB1*0201. Hum Immunol 1992, 34:107-114.
53. Kuijpers R.W., von dem Borne A.E., Kiefel V., Mueller-Eckhardt C.M., Waters A.H., Zupanska B., et al. Leucine33-proline33 substitution in human platelet glycoprotein IIIa determines HLA-DRw52a (Dw24) association of the immune response against HPA-1a (Zwa/PlA1) and HPA-1b (Zwb/PlA2). Hum Immunol 1992, 34:253-256.
54. Semana G., Zazoun T., Alizadeh M., Morel-Kopp M.C., Genetet B., Kaplan C. Genetic susceptibility and anti-human platelet antigen 5b alloimmunization. Role of HLA class II and TAP genes. Hum Immunol 1996, 46:114-119.
55. Sayeh E., Sterling K., Speck E., Freedman J., Semple J.W. IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferon-gamma response that is regulated by CD8+ T cells. Blood 2004, 103:2705-2709.
56. Wu S., Maslanka K., Gorski J. An integrin polymorphism that defines reactivity with alloantibodies generates an anchor for MHC class II peptide binding: a model for unidirectional alloimmune responses. J Immunol 1997, 158:3221-3226.
57. A1 and Bak epitopes. Blood 1991, 78:681-687.
58. Maslanka K., Yassai M., Gorski J. Molecular identification of T cells that respond in a primary bulk culture to a peptide derived from a platelet glycoprotein implicated in neonatal alloimmune thrombocytopenia. J Clin Invest 1996, 98:1802-1808.
59. Ahlen M.T., Husebekk A., Killie M.K., Skogen B., Stuge T.B. T-cell responses associated with neonatal alloimmune thrombocytopenia: isolation of HPA-1a-specific, HLA-DRB3*0101-restricted CD4+ T cells. Blood 2009, 113:3838-3844.
60. A1 typing and detection of GPIIb-IIIa complex. Br J Haematol 1985, 60:586-588.
61. Gruel Y., Boizard B., Daffos F., Forestier F., Caen J., Wautier J.L. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986, 68:488-492.
62. Jaegtvik S., Husebekk A., Aune B., Oian P., Dahl L.B., Skogen B. Neonatal alloimmune thrombocytopenia due to anti HPA-1a antibodies: the level of maternal antibodies predicts the severity of thrombocytopenia in the newborn. BJOG 2000, 107:691-694.
63. Giovangrandi Y., Daffos F., Kaplan C., Forestier F., Mac Alleese J., Moirot M. Very early intracranial haemorrhage in alloimmune fetal thrombocytopenia. Lancet 1990, 336:310.
64. Firan M., Bawdon R., Radu C., Ober R.J., Eaken D., Antohe F., et al. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001, 13:993-1002.
65. Ghetie V., Ward E.S. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunology Today 1997, 18:592-598.
66. Yoshida M., Claypool S.M., Wagner J.S., Mizoguchi E., Mizoguchi A., Roopenian D.C., et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity 2004, 20:769-783.
67. Chen P., Li C., Lang S., Zhu G., Reheman A., Spring C.M., et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010, 116:3384-3386.
68. Horsewood P., Kelton J.G. Macrophage-mediated cell destruction. Immunology of Transfusion Medicine 1993, 435-464. Marcel Dekker, New York. G. Garratty (Ed.).
69. Ravetch J.V., Bolland S. IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
70. Lin S.Y., Kinet J.P. Immunology: giving inhibitory receptors a boost. Science 2001, 291:445-446.
71. Wiener E., Abeyakoon O., Benchetrit G., Lyall M., Keler T., Rodeck C.H. Anti-HPA-1a-mediated platelet phagocytosis by monocytes in vitro and its inhibition by Fc gamma receptor (FcγR) reactive reagents. Eur J Haematol 2003, 70:67-74.
72. Warwick R.M., Vaughan J., Murray N., Lubenko A., Roberts I. In vitro culture of colony forming unit-megakaryocyte (CFU-MK) in fetal alloimmune thrombocytopenia. Br J Haematol 1994, 88:874-877.
73. Miyazaki R., Ogata H., Iguchi T., Sogo S., Kushida T., Ito T., et al. Comparative analyses of megakaryocytes derived from cord blood and bone marrow. Br J Haematol 2000, 108:602-609.
74. Panzer S., Auerbach L., Cechova E., Fischer G., Holensteiner A., Kitl Mayr W.R., et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995, 90:655-660.
75. Wuhrer M., Porcelijn L., Kapur R., Koeleman C.A., Deelder A., De Haas M., et al. Regulated glycosylation patterns of IgG during alloimmune responses against human platelet antigens. J Proteome Res 2009, 8:450-456.
76. A1: evidence for heterogeneity in the humoral response. Blood 1995, 85:3028-3033.
77. Morel-Kopp M.C., Daviet L., McGregor J., Kaplan C. Drawbacks of the MAIPA technique in characterising human antiplatelet antibodies. Blood Coagul Fibrinolysis 1996, 7:144-146.
78. Harrison C.R., Curtis B.R., McFarland J.G., Huff R.W., Aster R.H. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. Transfusion 2003, 43:1398-1402.
79. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
80. Robinson S.D., Hodivala-Dilke K.M. The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 2011, 23(5):630-637.
81. Tiller H., Killie M.K., Husebekk A., Skogen B., Ni H., Kjeldsen-Kragh J., et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstetricia et Gynecologica Scandinavica 2012, 91(1):79-86.
82. Shivdasani R.A., Rosenblatt M.F., Zucker-Franklin D., Jackson C.W., Hunt P., Saris C.J., et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell 1995, 81:695-704.
83. Suh T.T., Holmback K., Jensen N.J., Daugherty C.C., Small K., Simon D.I., et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 1995, 9:2020-2033.
84. Liu J., Fraser S.D., Faloon P.W., Rollins E.L., Vom B.J., Starovic-Subota O., et al. A betaPix Pak2a signaling pathway regulates cerebral vascular stability in zebrafish. Proc Natl Acad Sci U S A 2007, 104:13990-13995.
85. Nieswandt B., Bergmeier W., Rackebrandt K., Gessner J.E., Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 2000, 96:2520-2527.
86. Webster M.L., Sayeh E., Crow M., Chen P., Nieswandt B., Freedman J., et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006, 108:943-946.
87. Yang H., Chen P., Boyd S., Zhao X., Piran S., Li C., et al. Intravenous IgG transfusion restores angiogenesis and ameliorates intracranial hemorrhage in fetal and neonatal immune thrombocytopenia. Vox Sanguinis 2008, 95(Suppl. 1):36.
88. Curtis B.R., Edwards J.T., Hessner M.J., Klein J.P., Aster R.H. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000, 96:1574-1581.
89. Cooling L.L.W., Kelly K., Barton J., Hwang D., Koerner T.A.W., Olson J.D. Determinants of ABH expression on human blood platelets. Blood 2005, 105:3356-3364.
90. Taaning E. HLA antibodies and fetomaternal alloimmune thrombocytopenia: myth or meaningful?. Transfu Med Rev 2000, 14:275-280.
91. Tanaka T., Umesaki N., Nishio J., Maeda K., Kawamura T., Araki N., et al. Neonatal thrombocytopenia induced by maternal anti-HLA antibodies: a potential side effect of allogenic leukocyte immunization for unexplained recurrent aborters. J Reprod Immunol 2000, 46:51-57.
92. Curtis B.R., Fick A., Lochowicz A.J., McFarland J.G., Ball R.H., Peterson J., et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 2008, 48:358-364.
93. Kaplan C., Daffos F., Forestier F., Cox W.L., Lyon-Caen D., Dupuy-Montbrun M.C., et al. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets. Blood 1988, 72:340-343.
94. Murphy M.F., Waters A.H., Doughty H.A., Hambley H., Mibashan R.S., Nicolaides K., et al. Antenatal management of fetomaternal alloimmune thrombocytopenia-report of 15 affected pregnancies. Transfus Med 1994, 4:281-292.
95. Stanworth S.J., Hackett G.A., Williamson L.M. Fetomaternal alloimmune thrombocytopenia presenting antenatally as hydrops fetalis. Prenat Diagn 2001, 21:423-424.
96. Chakravorty S., Murray N., Roberts I. Neonatal thrombocytopenia. Early Hum Dev 2005, 81:35-41.
97. Bussel J.B., Zacharoulis S., Kramer K., McFarland J.G., Pauliny J., Kaplan C. Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatr Blood Cancer 2005, 45:176-183.
98. Kiefel V., Santoso S., Weisheit M., Mueller-Eckhardt C. Monoclonal antibody-specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood 1987, 70:1722-1726.
99. McMillan R. Antigen-specific assays in immune thrombocytopenia. Transfus Med Rev 1990, 4:136-143.
100. Socher I., Andrei-Selmer C., Bein G., Kroll H., Santoso S. Low-avidity HPA-1a alloantibodies in severe neonatal alloimmune thrombocytopenia are detectable with surface plasmon resonance technology. Transfusion 2009, 49:943-952.
101. Chong W., Metcalfe P., Mushens R., Lucas G., Ouwehand W.H., Navarrete C., et al. Detection of human platelet antigen-1a alloantibodies in cases of fetomaternal alloimmune thrombocytopenia using recombinant β3 integrin fragments coupled to fluorescently labeled beads. Transfusion 2011, 51:1261-1270.
102. Wu G.G., Kaplan C., Curtis B.R., Pearson H.A. Report on the 14th International Society of Blood Transfusion Platelet Immunology Workshop. Vox Sang 2010, 99:375-381.
103. Jallu V., Bianchi F., Kaplan C. Fetal-neonatal alloimmune thrombocytopenia and unexpected Glanzmann thrombasthenia carrier: report of two cases. Transfusion 2005, 45:550-553.
104. Bertrand G., Kaplan C., Kennel A., Perrier P., Moncharmont P. New mutation in the beta 3-integrin (GPIIIa) gene inducing HPA-1 genotyping discrepancies. Transfusion 2010, 50:1589-1591.
105. Bertrand G., Bianchi F., Chenet C., Martageix C., Blanchet P., Baumler M., et al. New mutation in the platelet β3-integrin gene: implication for the diagnosis of fetomaternal alloimmunization. Transfusion 2006, 46:2138-2141.
106. Curtis B.R., Bussel J.B., Manco-Johnson M.J., Aster R.H., McFarland J.G. Fetal and neonatal alloimmune thrombocytopenia in pregnancies involving in vitro fertilization: a report of four cases. Am J Obstet Gynecol 2005, 192:543-547.
107. Hurd C., Lucas G. Human platelet antigen genotyping by PCR-SSP in neonatal/fetal alloimmune thrombocytopenia. Pediatric Hematology: Methods and Protocols 2004, 71-78. Humana Press Inc, Totowa, NJ. N.J. Goulden, C.G. Steward (Eds.).
108. Gautier E., Benachi A., Giovangrandi Y., Ernault P., Olivi M., Gaillon T., et al. Fetal RhD genotyping by maternal serum analysis: a two-year experience. Am J Obstet Gynecol 2005, 192:666-669.
109. Scheffer P., Ait S.A., Verhagen O., Page-Christiaens G., Oepkes D., De Haas M., et al. Noninvasive fetal genotyping of human platelet antigen-1a. BJOG 2011, 118(11):1392-1395.
110. Bassler D., Greinacher A., Okascharoen C., Klenner A., Ditomasso J., Kiefel V., et al. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia. Transfusion 2008, 48:92-98.
111. Lee K., Beaujean F., Bierling P. Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002, 117:482-483.
112. Ranasinghe E., Walton J.D., Hurd C.M., Saul L., Smith G., Campbell K., et al. Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001, 113:40-42.
113. Allen D.L., Samol J., Benjamin S., Verjee S., Tusold A., Murphy M.F. Survey of the use and clinical effectiveness of HPA-1a/5b-negative platelet concentrates in proven or suspected platelet alloimmunization. Transfus Med 2004, 14:409-417.
114. Kiefel V., Bassler D., Kroll H., Paes B., Giers G., Ditomasso J., et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood 2006, 107:3761-3763.
115. Win N. Provision of random-donor platelets (HPA-1a Positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies. Vox Sang 1996, 71:130-131.
116. Massey G.V., McWilliams N.B., Mueller D.G., Napolitano A., Maurer H.M. Intravenous immunoglobulin in treatment of neonatal isoimmune thrombocytopenia. J Pediatr 1987, 111:133-135.
117. Knight M., Pierce M., Allen D., Kurinczuk J.J., Spark P., Roberts D.J., et al. The incidence and outcomes of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol 2011, 152:460-468.
118. Radder C.M., Brand A., Kanhai H.H. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001, 185:683-688.
119. Bussel J.B. Alloimmune thrombocytopenia in the fetus and newborn. Semin Thromb Hemost 2001, 27:245-252.
120. Kaplan C. Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002, 16:69-72.
121. Birchall J.E., Murphy M.F., Kaplan C., Kroll H. on behalf of the European Fetomaternal Alloimmune Thrombocytopenia Study Group. European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia. Br J Haematol 2003, 122:275-288.
122. Rayment R., Brunskill S.J., Soothill P.W., Roberts D.J., Bussel J.B., Murphy M.F. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2011, 5:CD004226.
123. Blanchette V.S., Semple J.W., Freedman J. Intravenous immunoglobulin and Rh immunoglobulin as immunomodulators of autoimmunity to blood elements. Autoimmune Disorders of Blood 1996, 35-77. AABB Press, Bethesda, MD. L.E. Silberstein (Ed.).
124. Salama A., Mueller-Eckhardt C., Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia: competitive inhibition of reticuloendothelial system function by sequestration of autologous red blood cells?. Lancet 1983, 2:193-195.
125. Crow A., Song S., Semple J.W., Freedman J., Lazarus A.H. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Br J Haematol 2001, 115:679-686.
126. Berchtold P., Dale G.L., Tani P., McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb-IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989, 74:2414-2417.
127. Rossi F., Kazatchkine M.D. Anti-idiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989, 143:4104-4109.
128. McKenzie S.E., Taylor S.M., Malladi P., Yuhan H., Cassel D., Chien P., et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999, 162:4311-4318.
129. Samuelsson A., Towers S.M., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
130. Crow A.R., Lazarus A.H. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-D immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know?. Transfus Med Rev 2008, 22:103-116.
131. Bowman J., Hartman C., Mentigolou S., Pollock J. Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia. Lancet 1992, 340:1034-1035.
132. Giers G., Wenzel F., Stockschlader M., Riethmacher R., Lorenz H., Tutschek B. Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion. Haematologica 2010, 95:1921-1926.
133. Lazarus A.H., Freedman J., Semple J.W. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus Sci 1998, 19:289-294.
134. Hansen R.J., Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002, 100:2087-2093.
135. Go R.S., Johnston K.L., Bruden K.C. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007, 92:283-284.
136. Ni H., Chen P., Spring C.M., Sayeh E., Semple J.W., Lazarus A.H., et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006, 107:2976-2983.
137. Paidas M.J., Berkowitz R.L., Lynch L., Lockwood C.J., Lapinski R., McFarland J.G., et al. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis. Am J Obstet Gynecol 1995, 172:475-479.
138. Kurz M., Stockelle E., Eichelberger B., Panzer S. IgG titer, subclass, and light-chain phenotype of pregnancy-induced HPA-5b antibodies that cause or do not cause neonatal alloimmune thrombocytopenia. Transfusion 1999, 39:379-382.
139. Bertrand G., Martageix C., Jallu V., Vitry F., Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. J Thromb Haemost 2006, 4:628-637.
140. van Gils J.M., Stutterheim J., van Duijn T.J., Zwaginga J.J., Porcelijn L., De H.M., et al. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. Mol Immunol 2009, 406-415.
141. Engelfriet C.P., Reesink H.W., Kroll H., Giers G., Bald R., Kanhai H., et al. Prenatal management of alloimmune thrombocytopenia of the fetus. Vox Sang 2003, 84:142-149.
142. Radder C.M., Brand A., Kanhai H.H. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?. Vox Sang 2003, 84:318-325.
143. Radder C.M., de Hann M.J.J., Brand A., Stoelhorst G.M., Veen S., Kanhai H.H. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. Early Hum Dev 2004, 80:65-76.
144. Radder C.M., Roelen D.L., van de Meers-Prins E.M., Claas F.H., Kanhai H.H., Brand A. The immunologic profile of infants born after maternal immunoglobulin treatment and intrauterine platelet transfusions for fetal/neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2004, 191:815-820.
145. Ward M.J., Pauliny J., Lipper E.G., Bussel J.B. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. Am J Perinatol 2006, 23:487-492.
146. Ghevaert C., Wilcox D.A., Fang J., Armour K.L., Clark M.R., Ouwehand W., et al. Developing recombinant HPA-1a-specific antibodies with abrogated Fcγ receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. J Clin Invest 2008, 118:2929-2938.
147. Doughty H.A., Murphy M.F., Metcalfe P., Waters A. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study. Br J Haematol 1995, 90:321-325.
148. Murphy M.F., Williamson L.M. Antenatal screening for fetomaternal alloimmune thrombocytopenia: an evaluation using the criteria of the UK national screening committee. Br J Haematol 2000, 111:726-732.
149. Murphy M.F., Williamson L.M., Urbaniak S.J. Antenatal screening for fetomaternal alloimmune thrombocytopenia: should we be doing it?. Vox Sang 2002, 83(Suppl. 1):409-416.
150. Bakchoul T., Boylan B., Sachs U.J., Bein G., Ruan C., Santoso S., et al. Blockade of maternal anti-HPA-1a-mediated platelet clearance by an HPA-1a epitope-specific F(ab') in an in vivo mouse model of alloimmune thrombocytopenia. Transfusion 2009, 49:265-270.
151. Zucker M.B., Ley A.B., Borrelli J., Mayer K., Firmat J. Thrombocytopenia with a circulating platelet agglutinin, platelet lysin, and a clot retraction inhibitor. Blood 1959, 14:148-161.
152. van Loghem J.J., Dorfmeijer H., van der Hart M., Schreuder F. Serological and genetical studies on a platelet antigen (Zw). Vox Sang 1959, 4:161-169.
153. Cohen H and on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2010 Annual Shot Report 2011, S. Knowles (Ed.).
154. Mueller-Eckhardt C., Kroll H., Kiefel V. and the members of the European PTP Study Group. Post-transfusion purpura. Clinical and Fundamental Aspects 1991, 249-255. John Libbey, Paris. C. Kaplan-Gouet, N. Schlegel, C. Salmon, J. McGregor (Eds.).
155. Warkentin T.E. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005, 127:35S-45S.
156. Lubenow N., Eichler P., Albrecht D., Carlsson L.E., Kothmann J., Rossocha W.R., et al. Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia: report of four cases and review of literature. Thromb Res 2000, 100:115-125.
157. Araujo F., Sa J.J., Araujo V., Lopes M., Cunha-Ribeiro L.M. Post-transfusion purpura vs heparin-induced thrombocytopenia: differential diagnosis in clinical practice. Transfus Medicine 2000, 10:323-324.
158. Wernet D., Sessler M., Dette S., Northoff H., Schnaidt M. Post-transfusion purpura following liver transplantation. Vox Sang 2003, 85:117-118.
159. Shulman N.R., Aster R.H., Leithner A., Hiller M.C. Immunoreactions involving platelets. V. Post-transfusion purpura due to a complement-fixing antibody against a genetically controlled platelet antigen. A proposed mechanism for thrombocytopenia and its relevance in "'autoimmunity.". J Clin Invest 1961, 40:1597-1620.
160. Watkins N.A., Smethurst P.A., Allen D., Smith G.A., Ouwehand W.H. Platelet αIIbβ3 recombinant autoantibodies from the B-cell repertoire of a post-transfusion purpura patient. Br J Haematol 2002, 116:677-685.
161. Woelke C., Eichler P., Washington G., Flesch B.K. Post-transfusion purpura in a patient with HPA-1a and GPIa/IIa antibodies. Transfus Med 2006, 16:69-72.
162. McFarland J.G. Detection and identification of platelet antibodies in clinical disorders. Transfus Apheresis Sci 2003, 28:297-305.
163. Mueller-Eckhardt C., Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1988, 57:163-167.
164. McFarland J.G. Posttransfusion purpura. Transfusion Reactions 2001, 187-212. AABB Press, Bethesda,MD. 2nd ed. M.A. Popovsky (Ed.).
165. A1)-negative platelets in a patient with post-transfusion purpura. Am J Hematol 2004, 76:258-262.
166. Godeau B., Fromont P., Bettaieb A., Beaujean F., Duedari N., Bierling P. Relapse of posttransfusion purpura after transfusion with frozen-thawed red cells. Transfusion 1991, 31:189-190.
167. Ballem P.J., Buskard N.A., Decary F., Doubroff P. Post-transfusion purpura secondary to passive transfer of anti-P1A1 by blood transfusion. Br J Haematol 1987, 66:113-114.
168. Brunner-Bolliger S., Kiefel V., Horber F.F., Nydegger U.E., Berchtold P. Antibody studies in a patient with acute thrombocytopenia following infusion of plasma containing anti-PlA1. Am J Hematol 1997, 56:119-121.
169. Warkentin T.E., Smith J.W., Hayward C.P.M., Ali A.M., Kelton J.G. Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood 1992, 79:2480-2484.
170. Boehlen F., Bulla O., Michel M., Reber G., de Moerloose P. HPA- genotyping and antiplatelet antibodies in female blood donors. Hematol J 2003, 4:441-444.
171. Bang A., Speck E.R., Blanchette V.S., Freedman J., Semple J.W. Recipient humoral immune responsiveness to allogeneic platelet transfusions is dependent on activation of inducible nitric oxide synthase. Blood 1996, 88:2959-2966.
172. Bang K.W.A., Speck E.R., Blanchette V.S., Freedman J., Semple J.W. Unique processing pathways within recipient antigen presenting cells determine IgG immune responsiveness against donor platelet antigens. Blood 2000, 95:1735-1742.
173. Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., et al. CD40 ligand on activated platelets triggers inflammatory reactions of endothelial cells. Nature 1998, 391:591-594.
174. + T cells and platelets: implications for CD40-CD40L signaling in atherosclerosis. J Pathol 2003, 201:288-295.